Pasar al contenido principal

PAPEL DE LA METALOPROTEASA 10 (MMP-10) EN ENFERMEDADES ISQUÉMICAS

PTQ-09-02-01941

•
Nombre agencia financiadora Ministerio de Ciencia e Innovación
Acrónimo agencia financiadora MICINN
Programa Programa Nacional de Contratación e Incorporación de RRHH
Subprograma Subprograma Torres Quevedo (PTQ)
Convocatoria Torres Quevedo
Año convocatoria 2009
Plan Estatal 2008-2011 Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica
Unidad de gestión Subdirección General de Formación e Incorporación de Investigadores
Centro beneficiario FUNDACION PARA LA INVESTIGACION MEDICA APLICADA
Identificador persistente http://dx.doi.org/10.13039/501100004837

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Synergistic effect of thrombin and CD40 ligand on endothelial matrix metalloproteinase-10 expression and microparticle generation in vitro and in vivo

  • Martínez de Lizarrondo, Sara
  • Roncal Mancho, Carmen
  • Calvayrac, Olivier
  • Rodríguez, Cristina
  • Varo, Nerea
  • Purroy, Ana
  • Lorente, Leonardo
  • Rodríguez, José Antonio
  • Doeuvre, Loïc
  • Hervás Stubbs, Sandra
  • Anglés-Cano, Eduardo
  • Páramo, José A.
  • Martínez-González, José
  • Orbe, Josune
Objective—Thrombin induces CD40 ligand (CD40L) and matrix metalloproteinases (MMPs) under inflammatory/prothrombotic conditions. Thrombin and CD40L could modulate endothelial MMP-10 expression in vitro and in vivo. Methods and Results—Human endothelial cells were stimulated with thrombin (0.1–10 U/mL), CD40L (0.25–1 μg/mL), or their combination (thrombin/CD40L) to assess MMP-10 expression and microparticle generation. Thrombin/CD40L elicited higher MMP-10 mRNA (5-fold; P<0.001) and protein levels (4.5-fold; P<0.001) than either stimulus alone. This effect was mimicked by a protease-activated receptor-1 agonist and antagonized by hirudin, a-protease-activated receptor-1, α-CD40L, and α-CD40 antibodies. The synergistic effect was dependent on p38 mitogen-activated protein kinase and c-Jun N-terminal kinase-1 pathways. Thrombin also upregulated the expression of CD40 in endothelial cell surface increasing its availability, thereby favoring its synergistic effects with CD40L. In mice, thrombin/CD40L further increased the aortic MMP-10 expression. Septic patients with systemic inflammation and enhanced thrombin generation (n=60) exhibited increased MMP-10 and soluble CD40L levels associated with adverse clinical outcome. Endothelial and systemic activation by thrombin/CD40L and lipopolysaccharide also increased microparticles harboring MMP-10 and CD40L. Conclusion—Thrombin/CD40L elicited a strong synergistic effect on endothelial MMP-10 expression and microparticles containing MMP-10 in vitro and in vivo, which may represent a new link between inflammation/thrombosis with prognostic implications., This work was funded through the "UTE project CIMA" (Universityof Navarra) and grants SAF2009-11949, SAF2009-12039 from Ministerio de Ciencia e Innovación (MICINN), and Red Temáticade Investigación Cardiovascular RECAVA (RD06/0014/0008 andRD06/0014/0027) and FIS/PS09/00143, FIS/PI-10-01572, and I3SNS-INT-11-063 from Instituto de Salud Carlos III (Madrid, Spain). Sara Martínez de Lizarrondo and Ana Purroy were sup-ported by a fellowship from the Education Department, Gobierno de Navarra. Carmen Roncal was supported by the Ministry of Scienceand Innovation MICINN-PTQ -09-02-01941.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Matrix metalloproteinase 10 is associated with disease severity and mortality in patients with peripheral arterial disease

  • Martínez Aguilar, Esther
  • Gómez-Rodríguez, Violeta
  • Orbe, Josune
  • Rodríguez, José Antonio
  • Fernández Alonso, Leopoldo
  • Roncal Mancho, Carmen
  • Páramo, José A.
Objective Peripheral arterial disease (PAD) is associated with poor prognosis in terms of cardiovascular (CV) morbidity and mortality. Matrix metalloproteinases (MMPs) contribute to vascular remodeling by degrading extracellular matrix components and play a role in atherosclerosis as demonstrated for MMP-10 (stromelysin-2). This study analyzed MMP-10 levels in PAD patients according to disease severity and CV risk factors and evaluated the prognostic value of MMP-10 for CV events and mortality in lower limb arterial disease after a follow-up period of 2 years. Methods MMP-10 was measured by enzyme-linked immunosorbent assay in 187 PAD patients and 200 sex-matched controls. Results PAD patients presented with increased levels of MMP-10 (702 ± 326 pg/mL control vs 946 ± 473 pg/mL PAD; P <.001) and decreased levels of tissue inhibitor of matrix metalloproteinase 1 (312 ± 117 ng/mL control vs 235 ± 110 ng/mL PAD; P <.001) compared with controls. Among PAD patients, those with critical limb ischemia (n = 88) showed higher levels of MMP-10 (1086 ± 478 pg/mL vs 822 ± 436 pg/mL; P <.001) compared with those with intermittent claudication (n = 99), whereas the MMP-10/tissue inhibitor of matrix metalloproteinase 1 ratio remained similar. The univariate analysis showed an association between MMP-10, age (P =.015), hypertension (P =.021), and ankle-brachial index (P =.006) in PAD patients that remained significantly associated with PAD severity after adjustment for other CV risk factors. Patients with the highest MMP-10 tertile had an increased incidence of all-cause mortality and CV mortality (P <.03). Conclusions Our results suggest that MMP-10 is associated with severity and poor outcome in PAD., This work was supported by the "UTE project CIMA" (University of Navarra) and Red de Investigación Cardiovascular RIC ( D12/0042/0009 ). V.G.R. was supported by a fellowship from the Foundation for Applied Medical Research (FIMA). C.R. was supported by the Spanish Ministry of Science and Innovation (MICINN-PTQ-09-02-01941).